F. Dejonckheere

Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.

T. Huizinga, J. Jansen, A. Finckh, 2015, Journal of managed care & specialty pharmacy.

Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

J. Jansen, S. Ogale, F. Buckley, 2014, Health and Quality of Life Outcomes.

FRI0414 Tocilizumab in methotrexate-intolerant or contraindicated patients – a cost-utility model for scotland

C. Gibbons, A. Diamantopoulos, F. Dejonckheere, 2013 .

PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

C. Gibbons, A. Diamantopoulos, D. Harland, 2012 .

Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

S. Sullivan, J. Carlson, S. Ogale, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

T. Huizinga, L. Sawyer, A. Finckh, 2014, PharmacoEconomics.

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.

S. Nathan, T. Maher, P. Thuresson, 2017, Journal of managed care & specialty pharmacy.

Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial Hypertension.

S. Nathan, T. Maher, F. Dejonckheere, 2017, Journal of managed care & specialty pharmacy.

Validity of Cost and Utility Results?

L. Sawyer, A. Diamantopoulos, S. Ogale, 2012, PharmacoEconomics (Auckland).